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Abstract
In recent years, cannabis has raised public awareness in many countries worldwide about its medical uses. 
The European cannabis market reached its peak during 2018 with investments of 500 million €. Greece introduced 
Law 4523/2018, which regulates the production and processing of medical cannabis. A start-up business plan 
was drawn up for a medical cannabis operation owned a 1 ha greenhouse to estimate the start-up costs and the 
costs of cultivating and processing medical cannabis under greenhouse conditions in Greece. The results of the 
present study revealed that the investment was estimated at 4,960,044 €. Net profit in the first year amounted to 
3,584,621.70 €, while the annual net profits from the second to the tenth year amounted to approximately 7.07 
billion. The Net Present Value with a value of 45,425,241.24 € is positive and the internal rate of return (IRR) is 
94.14%, which means that the investment can be characterized as profitable. 
Keywords: business plan, economic analysis, greenhouse cultivation, medical-cannabis facility, profitability
Introduction
Cannabis (Cannabis sativa L.) is a plant species 
mainly associated with its psychoactive use, which 
is due to the substance of tetrahydrocannabinol 
(THC). THC is the main psychoactive compound 
and the most well-known. As a result, it has several 
therapeutic properties that make the plant one of 
the most talked about plant species in the world 
(Kinghorn et al., 2017).
In recent years, cannabis has raised public 
awareness in many countries worldwide about 
its medical uses. This has subsequently led to a 
number of jurisdictions, either by decriminalizing 
cannabis or legalizing it for medicinal use, with 
some countries moving towards full legalization. 
With the growing acceptance of cannabis by 
the public, it is possible to create an entire 
cannabis industry to meet consumer demand and 
preferences, such as demand for cannabis-based 
medicines (EverBlu Capital, 2017).
The European cannabis market reached 
its peak during 2018, with investments of 500 
million €. This market has so far focused on the 
distribution of medical cannabis licenses. Across 
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greenhouse. The arrangement of this integrated 
production unit expressed in square meters is 
presented in Table 1.
The approach was to identify the various stages 
from infrastructure setup to the manufacturing of 
medicinal cannabis oil. The analysis was broken 
up into costs for business start-up, and then for 
cultivation and processing. For estimation of 
the total cost of cultivating and manufacturing 
medicinal cannabis, the present study was based 
on publicly available literature and research on 
medicinal cannabis industries in other countries 
(Caulkins, 2010; Hawken, 2013; Deloitte, 2016). 
Where data on the cultivation and manufacture 
of medicinal cannabis was not available, other 
crop types that exhibit a similar cost structure or 
cultivation technique to cannabis were used as 
proxies, such as cherry tomatoes (Laate, 2013). 
The construction cost was estimated at 41.4 € 
m-2. The equipment cost required for the medical 
cannabis cultivation (irrigation systems, drainage 
systems, fans, lighting, and heating systems) was 
set at 107.5 € m-2. The land price was 8809.5 € 
per ha. The security cost amounted to 17 € m-2. 
The cost of labor was estimated at 618 € per kg 
of dry inflorescences or 445 € m-2. The shipping 
cost was set at 0.25 € per kg of dry inflorescences. 
Europe, countries are reviewing the application of 
medical cannabis throughout the region. Countries 
such as France, the United Kingdom, and Spain 
are reviewing their current legislation. On the 
other hand, industry leaders (Germany, Italy and 
the Netherlands) focus on expanding the existing 
medical programs (Prohibition Partners, 2019).
In March of 2018, Greece introduced Law 
4523/2018, which regulates the production 
and processing of medical cannabis. This law 
was applied due to the desire to revitalize the 
crop industry and to trade in cannabis products. 
For the granting of approval for installation 
and authorization, the applicant must submit 
documents for all stages (from cultivation to 
processing and production of final medical 
cannabis products). On the basis of legislation, 
the cultivation will take place under greenhouse 
or indoor conditions (Folina et al., 2019). The 
objectives of this study were to estimate the start-
up costs and the costs of cultivating and processing 
medical cannabis under greenhouse conditions in 
Greece.
Materials and Methods  
A start-up business plan was drawn up 
for a medical cannabis operation owned a 1 ha 
Table 1. Arrangement of medical cannabis integrated production unit owned a 1 ha greenhouse
Description Land Area (m2) Cultivation Area (m2)
I. Greenhouse facilities
I.1 Vegetation zones 5,916 3,549.6
I.2 Flowering zones 8,875 5,325
I.3 Mechanical equipment area 640 -
Subtotal 15,431 8,874.6
II. Building premises
II.1 Mother Plants – Clone area 800 700
II.2 Service area 300 -
II.3 Trimming area 50 -
II.4 Drying area 60 -
II.5 Packaging area 170 -
II.6 Warehouse area 300 -
Subtotal 1,680 700
III. Exterior premises
III.1 Solar disinfection platform 350 -
III.2 Soil substrates storage area 280 -
III.3 Ovens area 60 -
Subtotal 690 -
VI. Other auxiliary premises
VI.1 Offices, restaurants and rooms (e.g. changing rooms) 1,100 -
Subtotal 1,100 -
Total area (m2) 18,901 9,574.6
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Regarding the consumables cost, it was estimated 
at 434 € m-2. About 80% of this cost, it is related 
to nutrients and the remaining 20% to pesticides. 
Costs of licenses, taxes and certification costs were 
estimated at 61.4 € m-2 or 85.2 € per kg of dry 
inflorescences (Deloitte, 2016).
The calculation of production capacity is based 
on greenhouse facilities. A three-week period is 
required to obtain a plant clone derived from the 
same plant (Miriello, 2017). In the present study, 
the total number of 1,401 mother plants was 
divided into three subsets of 467 mother plants 
each. The weekly production of each mother plant 
is between 6 and 10 cuttings (estimated at about 
7.58 cuttings) (Miriello, 2017). The first harvest 
of the first year was taken place on the 21st week 
(Miriello, 2017).
The profitability ratios in the current research 
were calculated using the following formulas 
(Wachira et al., 2014; Honoré et al., 2019):
Gross Profit Margin (%) = [(NS - PC) / NS] ×100 (1)
EBITA Margin (%) =
 = [(NS – PC – AC - SC – RDC) / NS] × 100           (2)
EBT Margin (%) = [(EBITA – I – A)/ NS] ×100  (3)
Net Profit Margin (%) = [(EBT - T)/ NS] ×100  (4)
where: 
EBITA = Earnings Before Interest, Taxes, and 
Amortization; EBT = Earnings before taxes and 
amortization; NS = Net Sales; PC = Production 
Costs; AC = Administrative Costs; SC =Sale 
Costs; RDC = Research and Development Costs; 
I = Interests of loans and working capital; A = 
Amortization and T = income Tax.
Finally, a SWOT analysis (strengths, weak-
nesses, opportunities and threats analysis; Tab. 
2) was performed to identify the internal and 
external factors that can have an effect on viability 
of greenhouse medical cannabis production in 
Greece.
Results and Discussions
The total investment budget was estimated 
at 4,960,044 € and distributed among building 
installation and infrastructures, mechanical-
technical equipment, other equipment, and 
intensive costs in the ratio of 42.28 : 51.56 : 3.08 : 
3.09, respectively. A bank loan of 3,968,035.20 €, 
accounting for 80% of total investment budget, 
was needed to complete the project. The long-term 
loan was estimated to last ten years with the first 
instalment paid off in the first year of the business. 
The instalment was determined as a half-year and 
amounted to 198,401.76 € (+3.6% interests). 
Table 2. SWOT analysis for greenhouse medical cannabis production in Greece
Strengths Weaknesses
• Ideal environment and climate conditions
• Possibility of creating mother plants/seeds 
with high genetic standards
• Direct access to the European market
• Lower average production from other 
countries
• Comparative advantage at a technical level – 
creating strategic alliances
• Direct access to public authorities
• Updated information about developments in 
the institutional framework
• Legislative gaps and a strict institutional 
framework for providing authorizations/ operations
• Institutional risk of the license framework for 
extension and modernization
• Participation of different and interested 
institutions/ ministries/ services.
• Lack of comparative domestic productivity/ 
profitability
• No common procedures in cultivation and 
production in comparison to other plant species
• Lack of experience from the public authorities
• Lacks in production from large markets on the 
legal framework.
Opportunities Threats
• High and growing demand from the 
European and international markets
• Easy corporate investments with rapid 
decrease of invested capital
• Export capacity under the institutional 
framework
• The unable policy and financial situation in Greece
• The issue of limited number of licenses
• The possible “negative” reaction of pharmaceutical 
companies
• Possibility of direct/ indirect income of 
competitive foreign companies
• Creation of “cartel” conditions because of the 
oligopolistic structures of industry
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Site preparation was estimated to last six 
months. During the first year, the final product of 
dry inflorescence was estimated at 3.171,84 kg, 
while, from the second year until the tenth year, 
it was estimated at 5.154,24 kg (Miriello, 2017). 
Taking into account that the price of final product 
of dry inflorescence was 3.00 € per kg (Freeman et 
al., 2018), the net sales amounted to 9,515,520.00 
€ in the first year, and to 15,462,720.00 € in the 
next years (Tab. 3).
The smooth operation of the new business 
required necessary additional working capital arise 
from the need for available resources and market 
conditions. Working capital was fully covered by 
a short-term bank loan. Annual working capital 
requirements were estimated at 518,776.17 € in 
the first year and ranged between 733,932.59 and 
738,549.82 € during the next years.
The administrative, sales, research and 
development costs were calculated as the 3, 5, and 
1% of the net sales (Deloite, 2016) (Tab. 3). Annual 
amortization was estimated at 370,192.50 €. The 
total income for the first year that the business 
starts operating was 9,515,520 €. From the second 
year, the incomes totaled 15,462,720 €. Net profit 
in the first year amounted to 3,584,621.70 €, while 
the annual net profits from the second to tenth 
year amounted to approximately 7.07 billion. The 
net profit margins ranged from 37.67% (first year) 
to 45.91% (tenth year) (Tab. 4).
The SWOT analysis revealed that the strongest 
points of medical cannabis production are the ideal 
environment and climate conditions in Greece, 
the possibility of creating mother plants/seeds 
with high genetic standards, the direct access 
to the European market and the lower average 
production from other countries (Folina et al., 
2019). On the other hand, the weaknesses are the 
legislative gaps and a strict institutional framework 
for providing authorizations/operations, the 
institutional risk of the license framework for 
extension and modernization, the participation of 
different and interested institutions/ ministries/
services as well as the lack of comparative 
domestic productivity/profitability (EMCDDA, 
2018) (Tab. 2). The high and growing demand 
from the European and international markets, 
as well as the fact that the medical cannabis 
operations are easy corporate investments with a 
rapid decrease of invested capital, can overpass all 
the weaknesses and threats that arose in medical 
cannabis production (Hawken, 2013; Folina et al., 
2019). 
Cannabis market is a fast-growing and 
emerging market on a European and global scale, 
governed by a dynamically evolving environment. 
The worldwide market for cannabis food is about 
200 million € showing steady upward trends in 
recent years (EverBlu Capital, 2017). About 250 
million EU citizens and 500 million worldwide 
even have legal access to cannabis for medical use. 
According to forecasts, if all European countries 
legalize cannabis use, the market is estimated to 
be around € 56.2 billion, of which € 35.7 billion 
relates to medical cannabis (Prohibition Partners, 
2019).
The results of the present study revealed 
that the 1-hectare medical cannabis operation 
in Greece is an investment of 4,960,044 €, which 
requires a working capital of approximately 
520,000 € in the first year, and from the second to 
the tenth it needs from 730,000 to 740,000 €, as 
well as it is a business with high depreciation. The 
Net Present Value with a value of 45,425,241.24 
€ is positive and the internal rate of return (IRR) 
is 94.14% with a discount rate of 4.5%, which 
Table 4. Ten-year profitability ratios of 1-hectare medical cannabis operation in Greece
Margin (%) 1st Year 2nd Year 3rd Year 4th Year 5th Year 6th Year 7th Year 8th Year 9th Year 10th Year
Gross Profit 





58.82 67.90 67.86 67.73 67.78 67.75 67.61 67.67 67.63 67.49
Earnings Before
Tax - EBT Margin 53.06 64.40 64.40 64.35 64.50 64.56 64.51 64.66 64.71 64.67
Net Profit Margin 37.67 45.72 45.72 45.69 45.80 45.83 45.80 45.91 45.95 45.91
Estimated Cost of Production for Medical Cannabis (Cannabis sativa L.) in Greece
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means that the investment can be characterized 
as profitable. However, it has to be noted that due 
to the desktop nature of the current analysis and 
the limited capacity to undertake consultations to 
fill in information gaps, some of the assumptions 
and costs are stronger than others. In order to 
provide further insight into the medical cannabis 
industry, particularly in the context of establishing 
an industry in Greece and differences that may 
arise in relation to overseas experience, additional 
analysis would help to inform assumptions that 
are both significant in driving overall costs and 
low in confidence in existing estimates.
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